~~<i id='DA055B1D16'><strike id='DA055B1D16'><tt id='DA055B1D16'><pre id='DA055B1D16'></pre></tt></strike></i>~~

Home» Wikipedia» Wikipedia

Wikipedia

author：knowledge 2025-10-01 03:45:13 Page View：29579

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What American doctors can learn from their Israeli counterparts
Next article： At least 13 dead in Texas as scorching temps continue

comprehensive

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Ending racial health disparities hinges on penalties, political will

AdobeThenation’swidespreadracialhealthdisparitieswon’tbeerasedwithoutchangestohowhealthcaresystemsar

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Trump surgeon general acknowledges mistakes during Covid

JeromeAdams,theU.S.surgeongeneralunderPresidentTrump,spokeThursdayattheSTATFutureSummit.STATTheTrump